A quantitative model for the dynamics of serum prostate-specific antigen as a marker for cancerous growth: An explanation for a medical anomaly

American Journal of Pathology

Volumn 158, Issue 6, 2001, Pages 2195-2199

  Swanson, Kristin R ^a,b   True, Lawrence D ^b   Lin, Daniel W ^c   Buhler, Kent R ^c   Vessella, Robert ^c   Murray, James D ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ANTIGEN DETECTION; ANTIGEN SPECIFICITY; ARTICLE; CANCER GROWTH; DISEASE MARKER; DYNAMICS; ENZYME SYNTHESIS; FOLLOW UP; MATHEMATICAL MODEL; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE EPITHELIUM; PROSTATE TUMOR; TUMOR VOLUME;

EID: 0034965728     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)64691-3     Document Type: Article

References (14)

1. Prostate specific antigen: A critical assessment of the most useful tumor marker for adenocarcinoma of the prostate
2. Total, free, and complexed PSA: Analysis and clinical utility
3. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer: A multi-institutional update
4. Prostate-specific antigen: Advances and challenges
5. Transition zone prostate specific antigen: Lack of use in prediction of prostate carcinoma
6. Rate of change in serum prostate specific antigen levels as a method for prostate cancer detection
7. Prostate-specific antigen variability in men without prostate cancer: Effect of sampling interval on prostate-specific antigen velocity
8. Prediction of prostate cancer volume using prostate-specific antigen levels, transrectal ultrasound, and systematic sextact biopsies
9. The volume of prostate cancer in biopsy specimen cannot reliably predict the quantity of cancer in the radical prostatectomy specimens on an individual basis
10. Characterization of a novel androgen-sensitive, prostate-specific antigen-producing prostatic carcinoma xenograft: luCaP 23
11. The significance of DNA-ploidy and s-phase fraction in node-positive (stage D1) prostate cancer treated with androgen ablation
12. Ki67 labelling index: An independent predictor of progression in prostate cancer treatment by radical prostatectomy
13. Implication of cell kinetic changes during the progression of human prostatic cancer